Serodus ASA and Evolva SA today signed the licensing agreement for EV-077.
Notice is hereby given of an extraordinary general meeting in Serodus ASA Monday 6 January 2014 at 14:00 hours CET in Gaustadalléen 21 (Forskningsparken), Oslo.
Serodus ASA has completed a private placement of 10 million shares directed towards selected leading Norwegian institutions and private investors. The subscription price was set at NOK 3,- per share, resulting in gross proceeds of NOK 30 million.
The clinical phase IIa study of SER100 in patients with isolated systolic hypertension has been initiated. The first patient has been enrolled in the study, and the company plans to enroll a total of thirty patients over the next few months. Thus, the clinical study is on schedule and Serodus expects to report the results in the second quarter of 2014.
Serodus ASA announced that a binding term sheet for EV-077 has been signed with the Swiss company, Evolva Holding SA.
On 11 September the CEO of Serodus, Eva Steiness, is giving her lecture "Evaluating how Risk Based Monitoring processes can be implemented to create a more cost-effective oversight model":
Serodus ASA publishes its Information Memorandum due to the merger with Phlogo ApS from Denmark. The IM can be downloaded from the Investor Relations pages.
An extraordinary general meeting was held on 8 July 2013. The protocol can be downloaded from the Investor Relations pages.
Notice is hereby given of an extraordinary general meeting to be held in Serodus ASA (the "Company") Monday 8th July 2013 at 12:00. The address is Gaustadallèen 21 in Oslo. All relevant documents will be published at this website.
The board of Serodus ASA (Oslo Axess:SER) and the owners of Phlogo ApS have signed an agreement to merge the companies. The transaction is conditional on approval of the shareholders in Serodus ASA. An extraordinary shareholders meeting will take place on 4th July 2013. More information about Phlogo.
Norne has issued its first analyst report on Serodus The report can be downloaded from the Investor Relations page.
The Canadian Intellectual Property Office has issued a notice of allowance for the company's patent application "Peptide conjugates modified N- and/or C-terminally by short charged peptide chains".
Consequently, the company's lead compound SER100 is or will be covered by patents in Australia, New Zealand, Japan, Europe, the USA and Canada.
The board of directors of Serodus ASA ("Serodus" or the "Company") has today resolved to offer between 4,000 and 1,500,000 New Shares with the aim of raising gross proceeds of up to NOK 4,500,000 in the Initial Public Offering (the "Offering") to be completed in connection with the listing of the Company's shares on Oslo Axess. Read more...
The Financial Supervisory Authority of Norway has approved the prospectus dated 7 March 2013 in connection with the initial public offering and the listing of Serodus ASA on Oslo Axess.The prospectus will be available here and at www.norne.no and will also be available free of charge at the business offices of Serodus ASA and Norne Securities AS. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
The ordinary general meeting of Serodus ASA will be held on Wednesday 27 February at 10:00 in Oslo Research Park, Gaustadalléen 21, 0349 Oslo. For more information, please visit our Investor Relations page.